Disparities in not recommending chemotherapy for individuals with newly diagnosed advanced endometrial cancer due to “patient risk factors”

• NCCN guidelines recommend systemic chemotherapy for frontline treatment of stage III/IV endometrial cancer. • In the NCDB (2004–2021), for 2.1% of such patients, chemotherapy was not recommended due to “patient risk factors”. • Increasing age, Black race, less education, and no or government insurance were associated with not recommending chemo. We sought to identify patient sociodemographic characteristics associated with not recommending chemotherapy due to “patient risk factors” for individuals diagnosed with advanced-stage endometrial cancer. Methods: We conducted a retrospective analysis of individuals newly diagnosed with stage III or IV endometrial cancer 2004–2021 utilizing the National Cancer Database (NCDB). The primary outcome was indication that “chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age […])” compared to chemotherapy recommended, regardless of administration. A logistic regression model examined associations between patient sociodemographic characteristics (age, race, ethnicity, education, type of insurance, urban/rural residence) and not recommending chemotherapy due to patient risk factors, adjusting for clinical factors including Charlson-Deyo comorbidity index scores, stage, histology, grade, and facility type. Among the 96,497 individuals included in the analysis, chemotherapy was not recommended for 2,030 (2.1%) due to “patient risk factors.” Increasing age, Black race, living in a zip code with less prevalent high school completion, and having no insurance or government insurance were independently associated with chemotherapy not being recommended after adjusting for clinical variables. Sensitivity analyses excluding subgroups more likely to have clinical contraindications, including those who did not have surgery, had a Charlson-Deyo comorbidity index score > 0, or died within 30 days of surgery found similar results. Despite National Comprehensive Cancer Network guidelines recommending chemotherapy for frontline treatment of advanced stage endometrial cancer, disparities in recommendations for chemotherapy were observed by sociodemographic factors including race, age, education, and insurance status.

Authors

Institutions

Publication Details

Journal
Gynecologic Oncology Reports
Published
2026-03-01
DOI
https://doi.org/10.1016/j.gore.2026.102072
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Disparities in not recommending chemotherapy for individuals with newly diagnosed advanced endometrial cancer due to “patient risk factors”

Katherine Cooke, Allison C. Dona, Sarah Boyle, Deanna Teoh et al.
Gynecologic Oncology Reports
Endometrial and Cervical Cancer Treatments
article

Disparities in not recommending chemotherapy for individuals with newly diagnosed advanced endometrial cancer due to “patient risk factors”

Katherine Cooke, Allison C. Dona, Sarah Boyle, Deanna Teoh, Rachel I. Vogel, Xuan Li
article en

Abstract

• NCCN guidelines recommend systemic chemotherapy for frontline treatment of stage III/IV endometrial cancer. • In the NCDB (2004–2021), for 2.1% of such patients, chemotherapy was not recommended due to “patient risk factors”. • Increasing age, Black race, less education, and no or government insurance were associated with not recommending chemo. We sought to identify patient sociodemographic characteristics associated with not recommending chemotherapy due to “patient risk factors” for individuals diagnosed with advanced-stage endometrial cancer. Methods: We conducted a retrospective analysis of individuals newly diagnosed with stage III or IV endometrial cancer 2004–2021 utilizing the National Cancer Database (NCDB). The primary outcome was indication that “chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age […])” compared to chemotherapy recommended, regardless of administration. A logistic regression model examined associations between patient sociodemographic characteristics (age, race, ethnicity, education, type of insurance, urban/rural residence) and not recommending chemotherapy due to patient risk factors, adjusting for clinical factors including Charlson-Deyo comorbidity index scores, stage, histology, grade, and facility type. Among the 96,497 individuals included in the analysis, chemotherapy was not recommended for 2,030 (2.1%) due to “patient risk factors.” Increasing age, Black race, living in a zip code with less prevalent high school completion, and having no insurance or government insurance were independently associated with chemotherapy not being recommended after adjusting for clinical variables. Sensitivity analyses excluding subgroups more likely to have clinical contraindications, including those who did not have surgery, had a Charlson-Deyo comorbidity index score > 0, or died within 30 days of surgery found similar results. Despite National Comprehensive Cancer Network guidelines recommending chemotherapy for frontline treatment of advanced stage endometrial cancer, disparities in recommendations for chemotherapy were observed by sociodemographic factors including race, age, education, and insurance status.

Gynecologic Oncology Reports
University of Minnesota (US), University of Minnesota Medical Center (US)
Openalex Percentile: Top 3%
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.